Related Experiment Video
Updated: Aug 1, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
[Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz]
M Hartmann1, J Brust, D Schuster
1Hautklinik, Universität, Heidelberg. Martin_Hartmann@med.uni-heidelberg.de
Abstract:
Efavirenz and nevirapine are frequently used drugs in antiretroviral therapy. Rashes are common side effects of these drugs. In this study, we examined the characteristics of efavirenz- and nevirapine-associated rashes. This prospective nonrandomized multicenter study included 662 HIV-infected patients (efavirenz: 325, nevirapine: 337) to determine incidence, duration, cross-reactivity, and outcome upon reexposure. Of the treated patients, 4.5% (n=30) developed rashes (nevirapine: 2.4% and efavirenz: 6.4%). In four patients treatment was not interrupted. Three patients were re-exposed to the initial drug without any side effects. Therapy with nevirapine or efavirenz does not have to be interrupted if rashes exhibit no blistering, mucosal manifestations, or systemic signs.
More Related Videos
12:03Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
Published on: September 5, 2016
10:29Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Related Concept Videos
Retrovirus Life Cycles
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Respiratory Syncytial Virus Disease
Cryptococcal Meningitis
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors